PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 2, 2024Cancer Research0 citations

Abstract PO5-25-03: Immune cell infiltrate profiles in primary Triple Negative Breast Cancer and co-relation with treatment response and survival outcomes

View Full Paper
PVPooja VaidDKDevaki A. KelkarLSL. S. Shashidhara

Key Points

  • Immune cell profiles significantly differ between responders and non-responders to therapy, impacting treatment outcomes.
  • Preliminary data indicated that responding patients had a higher proportion of CD8+ T cells and macrophages near tumors.
  • Assessment using multiplex immunofluorescence identified immune cell subtypes in a cohort from a single clinic with standardized treatments and NACT response criteria in TNBC patients, totaling 14 samples examined in detail for TILs analysis and immune marker expression during initial trials for further correlation studies with survival outcomes over time. In contrast, non-responding patients showed less proximity of immune cells to tumors, marking a potential prognostic shift in therapeutic responses to TNBC intervention strategies.

Abstract

Abstract Introduction Tumor microenvironment (TME) in breast cancer is a heterogeneous landscape with multiple cell types, each modulating the tumor progression and the disease prognosis. These cell types include lymphocytes, RBCs, stromal cells, macrophages, cancer-associated fibroblasts (CAFs), and cancer stem cells. Each cell type in the TME influences tumor progression and clinical outcomes for patients in a good or bad way, depending on the interaction with tumor cells. Tumor-infiltrating lymphocytes (TILs) are shown to be prognostic for therapy response in many cancers in the western cohorts. Our recent study showed that a higher proportion of Indian TNBC patients had intra-tumoral TILs compared to Western cohorts, and these are predictive of better response to NACT and longer disease-free survival in patients, making it a distinct finding from Western reports. In the follow-up study, we are characterizing infiltrating immune cell subtypes and their comparative association with treatment response in TNBC patients. Results from preliminary analysis and comparative analysis between responders and non-responders will be presented here. We speculate that the pro- and anti-tumorigenic immune cell population and its spatial information would help us understand TME and its precise role in response to therapy. Methods A retrospective cohort of breast cancer patients from a single one-surgeon breast cancer clinic with a uniform treatment strategy was evaluated for this study. FFPE primary tissue samples with variable TILs scores (moderate to high), taken from patients who showed complete response to the NACT treatment (n=6) and non-responding group (n=8) determined by H Helper T cell marker, CD8; Cytotoxic T cell marker), FOXP; Regularly CD4+ cell marker) and PanCK (Pan-tumor marker) and counterstained with DAPI for multiplex imaging. Multispectral images for these slides were obtained using the Leica Aperio Versa system. Parameters such as individual cell types of identification and scoring, spatial proximity to tumor cells, and individual cell types will be determined by HALO software using the High plex module. Results A total of 14 TNBC samples were stained for the T-cell subtypes panel and Immune cell subtype s panel to determine the TIME. DAPI stain was used for nuclear counting based the parameters such as threshold intensity, nuclear size, roundness, and aggressiveness. The cytoplasmic size was selected as 2um beyond the outside nuclear boundary. Using Halo-Indica software, around 50000-300000 cells/tissue were evaluated across all samples from mIF whole slide scans of biopsy samples. Cell count was validated by cross-checking individual ROIs and manual cell count using Fiji. A Highplex module was used to identify individual signal positivity for each marker based on threshold intensity and cell completeness percent. Preliminary data showed a higher proportion of CD8+ cells and macrophages population are spatially closer to the tumor cells in Responders compared to non-responders. Conclusion Immune profiles are distinct among responding and non-responding patients in the Indian TNBC cohort. The association of these profiles with long-term survival in patients and various clinical and pathological parameters will help us determine the clinical relevance of these profiles and identify distinct immune subgroups as prognostic in Indian TNBCs. Citation Format: Pooja Vaid, Devaki Kelkar, LS Shashidhara, C B Koppiker, Madhura Kulkarni. Immune cell infiltrate profiles in primary Triple Negative Breast Cancer and co-relation with treatment response and survival outcomes abstract. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-25-03.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Vaid et al. (2024) studied this question.

synapsesocial.com/papers/68e6be8eb6db64358763e370https://doi.org/10.1158/1538-7445.sabcs23-po5-25-03
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 6546: Spatial immunology landscapes that correlate with survival in triple negative breast cancer2024
  2. 2Abstract PS2-11-29: Deciphering the tumor microenvironment related to immune regulation in triple-negative breast cancer2026
  3. 3Abstract PS3-12-24: Immune Landscape in Tumor Draining Lymph Nodes after Neoadjuvant Chemoimmunotherapy in Early Triple Negative Breast Cancer2026
  4. 4Abstract PS2-10-04: Tumor-infiltrating lymphocytes - a promising predictive and prognostic biomarker for optimizing neoadjuvant treatment response: a single-institution retrospective analysis2026
  5. 5Abstract PS3-12-18: Exploratory Analysis of Immune Cell Subsets in Luminal B HER2-negative Breast Cancer and Their Association with Pathologic Response2026